E
OPTN

Ergoteles’s OptiNose OPTN Stock Holding History

Ergoteles’s Portfolio OPTN Stock Details OPTN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,580
Closed -$476K – 1496
2021
Q3 		$476K Sell
10,580
-80
-0.8% -$3.36K 0.02% 605
2021
Q2 		$497K Buy
+10,660
New +$544K 0.01% 809
2021
Q1 		– Sell
-3,460
Closed -$215K – 989
2020
Q4 		$215K Buy
+3,460
New +$212K 0.01% 593

Other funds holding OPTN

MPU
MVM Partners (UK) London, United Kingdom $149M AUM 6.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

Ergoteles's OPTN Position: Q4 2021 in Review

Ergoteles sold out of OptiNose (OPTN) in Q4 2021, closing a stake of 10,580 shares — an estimated $476K sold.

Ergoteles first reported a position in OPTN in Q4 2020 and held it in 3 quarters. The position peaked at $497K in Q2 2021. 44 funds tracked by Wall St. Rank hold OPTN as of Q4 2021.

  • Ergoteles reported no remaining OptiNose position as of Q4 2021 after selling out during the quarter.
  • Ergoteles sold 10,580 OptiNose shares in Q4 2021, an estimated $476K.
  • Ergoteles first reported a position in OptiNose in Q4 2020 and held it in 3 quarters.
  • Ergoteles's OptiNose position peaked at $497K in Q2 2021.
  • 44 funds tracked by Wall St. Rank held OptiNose as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.